1 / 43

Artificial Bladder: Filling the Void

Artificial Bladder: Filling the Void. Alexander Kutikov, MD (talk prepared in 2002, reviewed in 2011). Bladder Regeneration: Overview. Introduction Use of GI Segments Approaches to Bladder Replacement Alloplastic Bladders Tissue Engineered Bladders In-Situ Regenerated

lizettej
Download Presentation

Artificial Bladder: Filling the Void

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript


  1. Artificial Bladder: Filling the Void Alexander Kutikov, MD (talk prepared in 2002, reviewed in 2011)

  2. Bladder Regeneration: Overview • Introduction • Use of GI Segments • Approaches to Bladder Replacement • Alloplastic Bladders • Tissue Engineered Bladders • In-Situ Regenerated • In-Vitro Regenerated • Summary

  3. Introduction: Bladder Disease • 400 Million Suffer from Bladder Dz • Cancer • Trauma • Infection • Inflammation • Iatrogenic Injuries • Congenital Anomalies • Many Require Bladder Replacement

  4. Current Treatment • Bladder replacement w/ GI segments • > 100 year-old method • Remains the standard of care

  5. Problems w/ Using Bowel = GI Tissue - Designed to Absorb Solutes GU Tissue - Designed to Excrete Solutes

  6. Compliations of GI Neo-Bladders • Altered Electrolyte Metabolism • Altered Hepatic Metabolism • Abnormal Drug Metabolism • Infection • Calculus Formation • Nutritional Disturbances • Growth Retardation • Osteomalacia • Cancer

  7. Ideal Bladder Substitute • Adequate Urine Storage • Complete Evacuation of Urine (volitional) • Preserve Renal Function • Biocompatible • Resistant to Urinary Encrustation • Resistant to Bacterial Infection Must be superior to GI segments

  8. Approaches to Bladder Substitution • Alloplastic Bladders • Tissue Engineered Bladders • In-Situ Regenerated • In-Vitro Generated

  9. Alloplastic Organs

  10. Alloplastic Organs

  11. Alloplastic Bladder • First prosthetic bladder reported in 1960 • Box-shaped silicone reservoir attached to • anterior abdominal wall • Silicone tube brought out onto the skin served as outlet • Hydronephrosis due to ureteral prosthetic • anastomosis main reason for failure • No dog survived more than 1 month

  12. Alloplastic Bladder:Mayo Clinic Model Rigid polysulfone shell Distensible silicone shell Fluid 8 Fr silicone tubes in ureters • Implanted intraperitoneally • No dog survived > 10 wks

  13. Alloplastic Bladder: Reasons for Failure • Infections w/ abscess formation * • Urinary leaks at anastomoses * • Mechanical failure of device* • Urinary encrustation • Formation of constrictive capsule • RF 2o to Hydronephrosis * - Applies to Mayo Clinic Model

  14. Dacron-covered silicone tubes through renal parenchyma Subcutaneous compressible reservoirs Y-shaped Dacron-reinforced silicone reservoir drains into urethra Alloplastic Bladder: Aachen Model 7 years to develop

  15. Alloplastic Bladder: Aachen Model • Implanted into 5 sheep • Functioned effectively in 2 sheep for 18 mo • Urinary leakage in 3 animals due to anastamotic or material failure • Kidney structure and function preserved in all cases • No further publications on use of Aachen Model since 1996

  16. Alloplastic Bladder: Lessons Learned • Minimize anastomoses btwn living tissue and alloplasts • Transrenal-parenchymal insertion of urteral prosthesis offers hope • Infection is a major hurdle to overcome • Antibiotic-coated solid materials under investigation TISSUE ENGINEERING: potential solution to both problems

  17. Tissue Engineering: Definition Use of living cells to restore, maintain, or enhance tissues or organs

  18. Tissue Engineering: Principles Strategies for Treatment of Diseased/Injured Tissue: • Implantation of freshly isolated or cultured cells • In Situ tissue regeneration • Implantation of tissues assembled in vitro from cells and scaffolds

  19. Tissue Engineering: Principles Strategies for Treatment of Diseased/Injured Tissue: • Implantation of freshly isolated or cultured cells • In Situ tissue regeneration • Implantation of tissues assembled in vitro from cells and scaffolds

  20. Tissue Engineering: In Situ Regeneration

  21. Tissue Engineering: In Situ Regeneration

  22. Tissue Engineering: In Situ Regeneration

  23. Tissue Engineering: In Situ Regeneration

  24. Tissue Engineering: In Situ Regeneration

  25. Tissue Engineering: In Situ Regeneration

  26. Tissue Engineering: In Situ Regeneration • Numerous Materials Have been Tried as Matrices • Most Successful: • Small bowel submucosa • Acellular submucola of porcine small bowel • Bladder Acellular Matrix Grafts (BAMG) • Acellular collagen and elastin producedby stripping stromal and epithelial cellsfrom bladder wall

  27. Distended Normal Bladder S/p hemicystectomy of dome BAMG grafted bladder 7 mo post Tissue Engineering: In Situ Regeneration

  28. B/f Surgery S/p Surgery 7 mo s/p Surgery Tissue Engineering: In Situ Regeneration

  29. Tissue Engineering: In Situ Regeneration Histology a/f 4 months

  30. Tissue Engineering: In Situ Regeneration • Bladder wall structurally and functionallynearly identical to native bladder • No significant rejection of graft seen • Similar results obtained with SIS and BAMG grafts • Human trials with BAMG and SIS being attempted

  31. Tissue Engineering: Principles Strategies for Treatment of Diseased/Injured Tissue: • Implantation of freshly isolated or cultured cells • In Situ tissue regeneration • Implantation of tissues assembled in vitro

  32. Tissue Engineering: In Vitro Assembly

  33. Tissue Engineering: In Vitro Assembly

  34. Tissue Engineering: In Vitro Assembly

  35. Tissue Engineering: In Vitro Assembly

  36. SMOOTH MUSCLE UROTHELIUM Tissue Engineering: In Vitro Assembly

  37. Tissue Engineering: In Vitro Assembly • Potential for genetic/phenotypic screeing of harvested cells • allows selection against transformed phenotypes

  38. Tissue Engineering: In Vitro Assembly • Potential for genetic/phenotypic screening of harvested cells • allows selection against transformed phenotypes • Cells could also be genetically modified to acquire desired properties (e.g. antimicrobial, growth factors, etc.)

  39. Tissue Engineering: In Vitro Assembly Bx to implant of graft = 5 weeks

  40. Tissue Engineering: In Vitro Assembly

  41. Tissue Engineering: In Vitro Assembly Native bladder wall Tissue-engineered Neo-bladder

  42. Tissue Engineering: In Vitro Assembly • Function of Tissue Engineered Neo-Bladder: • Mean bladder capacity was 95% of precystecomy volume • Mean compliance was no different than preoperative values

  43. Summary • GI Segments: employed as neobladders >100 years; it’s time for change. • Alloplastic Neobladders: little hope w/ current materials. • Tissue Engineering: hold much hope, • but remains experimental. Human studies humbling to date.

More Related